Semakula Barbara, Rittenbach Jon V, Wang Jun
Department of Pathology and Laboratory Medicine, Loma Linda University Medical Center, Loma Linda, CA 92354, USA.
Arch Pathol Lab Med. 2006 Apr;130(4):558-60. doi: 10.5858/2006-130-558-HLPLD.
Posttransplantation lymphoproliferative disorders (PTLD) are a heterogeneous group of monoclonal or polyclonal lymphoproliferative lesions that occur in immunosuppressed recipients following solid organ or bone marrow transplantation, including 4 categories: (1) early lesions (reactive plasmacytic hyperplasia, and infectious-mononucleosis-like PTLD), (2) polymorphic PTLD, (3) monomorphic PTLD (including B-cell neoplasms and T-cell neoplasms), and (4) Hodgkin lymphoma (HL) and HL-like PTLD in the current World Health Organization classification. Although HL-like PTLD has been grouped with classic HL PTLD, controversy remains as to whether it is truly a form of HL or whether it should be more appropriately considered as a form of B-cell PTLD. The current available literature data indicate the presence of important immunophenotypic, molecular genetic, and clinical differences between HL PTLD and HL-like PTLD, suggesting that HL-like PTLD is in fact most often a form of B-cell PTLD. Distinction from true HL may be important for clinical management and prognosis.
移植后淋巴组织增生性疾病（PTLD）是一组异质性的单克隆或多克隆淋巴组织增生性病变，发生于实体器官或骨髓移植后的免疫抑制受者，包括4类：（1）早期病变（反应性浆细胞增生和传染性单核细胞增多症样PTLD），（2）多形性PTLD，（3）单形性PTLD（包括B细胞肿瘤和T细胞肿瘤），以及（4）在当前世界卫生组织分类中的霍奇金淋巴瘤（HL）和HL样PTLD。尽管HL样PTLD已与经典HL PTLD归为一类，但关于它是否真的是HL的一种形式，还是应更恰当地视为B细胞PTLD的一种形式，仍存在争议。目前可用的文献数据表明，HL PTLD和HL样PTLD之间存在重要的免疫表型、分子遗传学和临床差异，这表明HL样PTLD实际上最常是B细胞PTLD的一种形式。与真正的HL区分开来可能对临床管理和预后很重要。
